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Abstract
Specific CD8+ T cells (CTLs) play an important role in resolving protracted infection with 
hepatitis B and C virus in humans and lymphocytic choriomeningitis virus (LCMV) in mice. The 
contribution of individual CTL specificities to chronic virus control, as well as epitope-specific 
patterns in timing and persistence of antiviral selection pressure remain, however, incompletely 
defined.
To monitor and characterize the antiviral efficacy of individual CTL specificities throughout the 
course of chronic infection, we co-inoculated mice with a mixture of wildtype LCMV and 
genetically engineered CTL epitope-deficient mutant virus. A quantitative longitudinal assessment 
of viral competition revealed that mice continuously exerted CTL selection pressure on the 
persisting virus population. The timing of selection pressure characterized individual epitope 
specificities, and its magnitude varied considerably between individual mice.
This longitudinal assessment of “antiviral efficacy” provides a novel parameter to characterize 
CTL responses in chronic viral infection. It demonstrates remarkable perseverance of all antiviral 
CTL specificities studied, thus raising hope for therapeutic vaccination in the treatment of 
persistent viral diseases.
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Introduction
Estimated 350 and 170 million people worldwide are chronically infected with hepatitis B 
(HBV) and C virus (HCV), respectively, and thirty million people live with HIV (1). The 
resulting morbidity and mortality render these diseases major global health challenges, while 
strategies for therapeutic viral clearance remain unsatisfactory. In accordance with initial 
observations in LCMV-infected mice (2, 3), cytotoxic CD8+ T lymphocytes (CTL) have 
been shown to play a key role in containing and resolving persistent viral infections in 
humans. HIV and HCV viremia decline when the antiviral CD8+ T cell response emerges 
(4-6). HIV long-term non-progression as well as spontaneous clearance of HCV is 
associated with so-called "protective" HLA molecules (7, 8), corroborating the role of MHC 
class I-restricted T cells in viral control. Moreover, CD8+ T cell depletion experiments in 
simian immunodeficiency virus-infected macaques and HBV- or HCV-infected 
chimpanzees underscore the importance of CTLs in the acute phase of infection, as well as 
in long-term control and acquired immunity (9, 10).
Infection of mice with the Clone 13 (Cl13) strain of lymphocytic choriomeningitis virus 
(LCMV) has demonstrated governing principles of CTL responses in chronic viral infection 
(11-13), finding subsequent confirmation in the aforementioned human diseases (1). As a 
common finding, persisting viral infections with continuous exposure to a high antigen 
burden tend to subvert specific CTL responses (1). Fig. 1A,B and Figs. S1A-C provide an 
illustration of reduced CTL functionality in Cl13 chronically infected mice, as compared to 
CTLs originating from acute infection with the Armstrong strain of LCMV. If not physically 
deleted (11), such CTLs gradually lose IL-2 and TNF-α production but tend to retain IFN-γ 
secretion and CD107a expression (12-14). “Exhaustion” therefore refers to mostly mono- to 
bifunctional CTL populations with a relative paucity in polyfunctional cells, and is 
associated with the upregulation of inhibitory receptors such as programmed cell death 1 
(PD-1, Fig. 1B, (15)).
The course of Cl13 infection in C57BL/6 mice has resemblance to spontaneous HBV or 
HCV control in humans in that the immune system eventually prevails and clears the virus 
from blood after 2-3 months (16). The underlying mechanisms remain, however, 
incompletely understood. Specific antibody responses and T follicular helper cell-driven 
germinal center reactions are necessary but not sufficient to resolve protracted infection (17, 
18). C57BL/6 (H-2b) mice also mount a very potent and broad antiviral CTL response, 
comprising 28 known epitope specificities (19). MHC class I deficiency results in life-long 
viral persistence, documenting the key contribution of CTLs to control of chronic LCMV 
infection (3). However, several factors have rendered it difficult to address the contribution 
of individual CTL specificities to clearance: I) Virus strain and dose as well as host 
parameters influence LCMV persistence. In settings of life-long viremia, LCMV-specific 
CTLs may eventually be deleted (11, 20). Conversely, CTL function recovers when cognate 
antigen levels decline in Cl13-infected C57BL/6 mice, irrespective of the mechanism for 
viral clearance (21, 22). Thus, resurgence of CTL functionality might be a cause or a 
consequence of declining viremia. II) CTL epitope-mutant viruses evoke compensatory 
alterations in CTL immunodominance hierarchies (23). Therefore, a comparison of 
clearance kinetics of epitope-mutant and wild type viruses, when individually administered 
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to animals, cannot assess the efficacy of the respective CTL population. III) 
Immunodominance hierarchies change significantly as chronic infection progresses (13). 
Hence the undisputed role of CTLs for chronic virus control, as established by CD8+ T cell 
depletion and gene knockout in experimental animals (2, 24), might have reflected the 
efficacy of subdominant CTL specificities (25), which surface during protracted infection 
and tend to be more functional than early immunodominant ones (23). The combined 
evidence of several recent reports supported the idea that the phenotypically “exhausted” 
CTL response is of functional relevance (14, 26-28). Still, the protective efficacy of 
individual antiviral CTL specificities and their contribution to resolution of chronic virus 
infection remained to be defined.
Here we exploited viral reverse genetics for a novel methodological approach to assess the 
antiviral selection pressure exerted by individual CTL specificities of chronically infected 
mice. This quantitative analysis of the extent, timing and inter-individual variability of 
protective CTL efficacy lends a novel perspective on CTL-mediated control of chronic viral 
infection.
Materials and Methods
Ethics statement
Animal experiments were performed at the Universities of Geneva and Zurich, and have 
been approved by the Direction générale de la santé (permissions 1005/3312/2 and 
1005/3312/2-R) of the Canton of Geneva, and the Cantonal Veterinary Office of the Canton 
of Zurich (permission 176/2005), respectively. All animal experiments were performed in 
accordance with the Swiss law for animal protection.
Mice
C57BL/6, H-2Db−/− and H-2Kb−/− (29) mice were bred at the Institute for Laboratory 
Animal Sciences of the University of Zurich, Switzerland and BALB/c mice were obtained 
from Harlan laboratories. All mice were maintained in specific pathogen-free conditions.
Generation and titration of viruses, antibody neutralization and infection of mice
LCMV Clone 13 (Cl13) and variants thereof were generated from cDNA by reverse genetic 
techniques (30). To generate a « tagged » virus for discrimination from a competitor virus 
by TaqMan RT-PCR (Fig. 1C,E) and to introduce single amino acid changes resulting in 
deletion of select CTL epitopes (Fig. 1D, Fig. S1E-I) we used standard two-way site-
directed mutagenesis on the LCMV S segment expression plasmid pI-S-Cl13(−)* (30) that 
was used for the generation of LCMV Cl13 from cDNA (primer sequences avilable from the 
authors upon request). The codons of the mutated amino acids were chosen to be as different 
from the wildtype amino acid’s codons as possible, to avoid viral reversion by a single 
nucleotide change. All viruses were grown on BHK-21 cells. Infectious titers and the 
potency of antiviral antibodies were assessed by immunofocus assay and focus reduction 
neutralization tests, respectively, as previously described (30, 31). Mice were infected with a 
10:1 ratio of wildtype : epitope-mutant virus, i.e.2×106 PFU and 2×105 PFU, respectively, 
mixed for intravenous (i.v.) co-administration in one single syringe. When given as 
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individual infection, Cl13 was given at a dose of 200 PFU (Fig. S1E-I) or 2×106 PFU i.v. 
(Fig. 1, Fig. S1A-C), and 105 PFU LCMV Armstrong were administered intraperitoneally 
(i.p.).
T cell assays
Intracellular cytokine assays were performed on splenocytes as previously described (30, 
32). For the assessment of degranulation, anti-CD107a antibody was added to the 
restimulation culture at a concentration of 1 μg/ml. Peptides (90% pure) of the sequences 
displayed in Fig. 1D and Fig. S1E-I were purchased from ProImmune. MHC class I 
tetramers (GP33: H-2Db/KAVYNFATC; GP276: H-2Db/ SGVENPGGYCL) were supplied 
by Beckman Coulter. Antibodies were from BD biosciences and Biolegend. Flow cytometry 
was performed on BD FACSCalibur and Beckman Coulter Gallios flow cytometers.
Assessment of viral loads by TaqMan RT-PCR
Mouse serum was collected into microtainer tubes (BD Biosciences) and viral RNA was 
extracted using the Qiagen 96 DNA blood kit. TaqMan RT-PCR was performed using 
Invitrogen Superscript III One Step Platinum Taq. Primers and probes were ordered through 
Sigma Aldrich. To detect the natural Cl13 NP sequence (present in epitope-escape variants) 
we utilized fwd primer 5`-ACTGACGAGGTCAACCCGG-3’, reverse primer 5`-
CAAGTACTCACACGGCATGGA-3’ and the probe 5`-FAM- 
CTTGCCGACCTCTTCAATGCGCAA-BHQ1-3’ (33). For detection of the “tagged” 
sequence (in epitope-sufficient wildtype virus, utilized in competition experiments), we 
designed fwd primer 5'-TGCTCGTGAGGCCTGGTT-3', reverse primer 5'-
TTAAGCAGGACAGCAAATATAGTCATG-3' and the probe 5'-HEX-caaTttGtTTaggCgc-
BHQ1-3' (small letters indicating locked nucleotides). Measurements were performed on an 
ABI TaqMan device. Absolute viral RNA copies per 3.3 μl of serum were calculated by 
comparison to in vitro transcript RNAs (compare Fig. S1J-L), which served as reference in 
all TaqMan assays. Further details on cycling conditions and the generation of in vitro 
transcripts are available from the authors upon request.
Quantification of epitope-specific CTL selection pressure
(a) The mathematical model to determine selection: To infer the selection pressure 
exerted by CTLs specific for individual epitopes, we used the following mathematical model 
published by Ganusov and De Boer (34). Wildtype, w(t), and epitope-mutant virus, m(t), are 
assumed to grow at a time-dependent rate r(t), and die at a common time-dependent death 
rate d(t). In addition, the wildtype virus can be killed at a time-dependent killing rate k(t) 
denoting the epitope-specific CTL response. The change of wildtype and epitope-mutant 
virus over time was then described by the following system of ordinary differential 
equations.
(1)
(2)
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By considering the ratio of wildtype and epitope-mutant virus we could directly estimate the 
time-dependent CTL selection pressure (TDSP), k(t), exerted on the epitope in question. 
Defining z(t) = w(t)/m(t) we obtained
(3)
Thus, the selection pressure could be obtained from the change over time of the log ratio of 
wildtype and epitope-mutant virus. Since we were only interested in the change of ln(z(t)) 
over time, the initial ratio between wildtype and epitope-mutant was irrelevant. The 
parameter k(t) denotes the net-selection pressure, i.e., the difference between the selective 
advantage of the epitope-mutant compared to the wildtype, due to the escaped CTL 
response, and the disadvantage due, for example, to fitness costs. Hence, negative values of 
k(t) could indicate that the fitness cost of the epitope-mutant outweighs its selective 
advantage over the wildtype. In most instances, however, negative k(t) values are due to 
viral loads falling below detection limits, thus preventing an accurate determination of 
wildtype : mutant virus ratios at the respective time points (outlined in more detail in section 
(c) below). It is equally conceivable that mechanisms such as transient and 
compartmentalized CTL selection pressure result in periods of negative k(t).
(b) Application to the data: The time-dependent selection curve k(t) for each individual 
mouse were determined by using Eq. (3). A smooth cubic spline function was fitted to the 
individual data points given by −ln(w(ti)/m(ti)), where w(ti) and m(ti), i=1,…,n denote the 
measured viral load for wildtype and epitope-mutant virus, respectively, at time point ti. The 
time-dependent selection curves k(t) were then estimated by the first derivative of the 
obtained spline function. Measurements of wildtype and epitope-mutant virus below the 
detection limit (100 copies / 3.3 μl) were set to half of the detection limit (50 copies/ 3.3 μl). 
Using other values for the replacement, e.g. setting measurements below the detection limit 
to 99 copies / 3.3 μl did not change the results overall.
(c) Calculating the average selection coefficient κ: We assumed that the observed 
variation in the log-ratio between wildtype and epitope-mutant virus in BALB/c mice 
represented effects unrelated to the epitope specific CTL response. Therefore, for each 
epitope, we used the BALB/c mice to calculate a function, kBG(t), representing background 
noise in k(t) due to fluctuation of ratios of wildtype and epitope-mutant virus in the absence 
of selection and also reflecting potential fitness costs for the epitope-mutant viruses. To this 
end, a smooth cubic spline function was fitted to the pooled data of all BALB/c mice tested 
for a given epitope, and the first derivative was estimated to obtain kBALB/c(t). The 
“background-selection” function, kBG(t), was then determined by performing a bootstrap 
analysis with 10,000 replicates re-sampling from the data of the BALB/c mice and taking 
the time-wise 97.5% upper limit of the obtained values of kBALB/c(t).
To calculate the average selection coefficient over time for each individual mouse we 
considered only those parts of the individual selection curves where the individual selection 
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was larger than the estimated background noise, k(t)> kBG(t). Hence, the average selection 
coefficient κ until time point T was calculated by
(4)
with k+(t)= k(t)−kBG(t) if k(t)> kBG(t) and 0 otherwise. Hereby, t+ denoted the total length 
of the time intervals in [0,T] where k(t)> kBG(t). By only considering the time intervals 
where the individual selection was larger than the background selection, k(t)>kBG(t), we 
accounted for the fact that negative selection can be due to viral loads falling below 
detection limits (see e.g. wt virus in strongly selecting C57BL/6 mice; top panels of Fig. 2). 
This prevented an accurate determination of wildtype : mutant virus ratios at the respective 
time points, with TDSP artificially turning negative. By considering only k(t)>kBG(t) values, 
our method to calculate the average selection coefficient κ focused on unambiguous signals 
of selection.
(d) Time-dependent selection bands for C57BL/6 mice: Analogously to the function 
representing background noise in k(t) (due to fluctuation in ratios of wildtype and epitope-
mutant virus in the absence of selection), time-dependent selection bands were calculated for 
the C57BL/6 mice, individually for each epitope. A smooth cubic spline function was fitted 
to the pooled data of all C57BL/6 mice for one epitope, and the first derivative was 
estimated to obtain kC57BL/6(t). A 95% confidence band for kC57BL/6(t) was calculated by 
performing a bootstrap analysis with 10,000 replicates re-sampling from the data of the 
C57BL/6 mice and taking the time-wise 97.5% upper limit and 2.75% lower limits of the 
obtained values of k
 C57BL/6 (t). For these latter analyses, only those C57BL/6 mice were 
considered, where the average selection pressure, κ, was larger than the maximal selection 
pressure determined for BALB/c mice.
Results
To determine the protective efficacy of individual CTL specificities in protracted LCMV 
infection we designed viral in vivo competition experiments (Fig. 1C). We infected 
C57BL/6 mice with 2×106 PFU of wildtype cDNA-derived Cl13 virus, in combination with 
2×105 PFU of genetically engineered CTL epitope-mutant virus (see below). In this setting, 
a relative enrichment of the epitope-mutant virus over time would be evidence of CTL 
selection pressure on the epitope in question. We engineered CTL epitope-mutant viruses, 
differing from the wildtype virus by only one amino acid substitution in the GP276, GP33 or 
NP396 CTL epitope, respectively (Fig. 1D). Each of these mutations were known and/or 
predicted to prevent MHC presentation to CD8+ T cells (H-2Db for GP276 and NP396; 
H-2Db and H-2Kb for GP33 (35)). Conversely, these mutations did not affect their 
neutralization by monoclonal antibodies or virus-specific antiserum (Fig. S1D). This was 
expected since neutralizing antibodies are uniformely targeted against the outer globular 
GP-1 domain of the viral glycoprotein complex whereas the mutations introduced were 
situated in the membrane-proximal glycoprotein stalk (GP276), signal peptide (GP33) and 
virion-internal nucleoprotein (NP396). We validated the epitope-mutant viruses by verifying 
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their inability to induce CTL responses against the wildtype and mutated epitope sequences 
and we also tested the lack of recognition of the mutant epitopes by wildtype virus-induced 
CTLs (Fig. S1E-I). To individually quantify wildtype and epitope-mutant viruses in co-
infected animals, we « tagged » the wildtype virus by introducing non-coding changes in the 
target sequence of our TaqMan RT-PCR assay (Fig. 1E). As expected, this « tagged » wt 
virus reached normal titers and persisted in the blood of mice analogously to non-tagged wt 
virus (Fig. 1F). The respective TaqMan assays were validated for accuracy and 
discrimination of the two viral target sequences (Fig. S1J-L; Materials and Methods), and 
we utilized them to individually follow serum loads of epitope-mutant and wildtype virus in 
co-infected animals over time (Fig. 1G). From these values, we calculated ratios of epitope-
mutant:wildtype virus (Fig. 1H) and derived a time-dependent selection coefficient k(t), 
which quantifies the time-dependent selection pressure (TDSP) CTLs exert on the epitope 
under study (Fig. 1I; see also Materials and Methods). Given the MHC molecules presenting 
these epitopes, CTL-driven selection of epitope-mutant virus was only expected in C57BL/6 
(H-2b) but not in BALB/c mice of the H-2d haplotype (control). Cohorts of 26, 15 and 12 
inbred C57BL/6 mice were subject to coinfection experiments with GP276-, GP33- or 
NP396-deficient epitope-mutant and wildtype competitor virus, respectively. We collected 
serum samples over time to monitor viral loads and calculate TDSP by GP276-, GP33- and 
NP396-specific CTLs. Viral load curves and deducted selection coefficients are shown in 
Figure 2 (representative animals) and Figs. S2-S4. 6-10 BALB/c mice per epitope were 
included as controls. As expected, wt and epitope-mutant viruses showed largely parallel 
clearance kinetics in these H-2d non-selecting mice. There were minor residual fluctuations 
in epitope-mutant:wildtype virus ratios. These were used to calculate a time-dependent 
background noise in the selection coefficient k(t) for each epitope, which we defined as 
being unrelated to specific CTL selection pressure (gray area in Fig. 2 and Figs. S2-S4). 
Unlike in BALB/c mice, C57BL/6 mice tended to clear the wt virus more readily than 
GP276-, GP33- or NP396-deleted viruses, indicating selection pressure on the respective 
epitopes. The timing and magnitude of selection pressure (red lines in Fig. 2 and Figs. S2-
S4) exhibited, however, extensive diversity between individual animals. Exemplary 
C57BL/6 mice with either strong or weak to undetectable selection pressure as shown in Fig. 
2 represented the extremes of a spectrum (Figs. S2-S4). This finding matched earlier 
observations that Cl13 control in the late phase of infection varies considerably within 
cohorts of genetically identical mice (17, 20). The resulting diversity of individual TDSP 
curves is illustrated in Fig. 3A. Conversely, very minor fluctuations of TDSP in BALB/c 
mice attest to the technical accuracy and overall reliability of the measurements and 
experimental set-up. Note that periods of negative TDSP in C57BL/6 mice were mostly due 
to viral loads falling below detection limits (see e.g. Fig. 2 top panels and Materials & 
Methods). The LCMV polymerase is error-prone, and viral variants with increased fitness 
can be selected for in chronic infection. Such random mutation and selection occurs, 
however, irrespective the MHC haplotype of the host. Consistently low TDSP values in 
BALB/c mice indicate therefore that the selection of epitope-mutant viruses, as observed in 
C57BL/6 mice, was not due to random mutations but resulted from MHC-restricted CTL 
pressure on the very epitope, which had been deliberately mutated. Next we calculated the 
area under each mouse’ individual selection curve (striped in Fig. 1I; see Materials & 
Methods). Thereby we obtained an average value for epitope-specific CTL pressure (κ) 
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during time intervals the TDSP curve was above background. The resulting values showed 
that about 60-75% of C57BL/6 mice exerted CTL selection pressure on GP276, GP33 and 
NP396 above BALB/c backgrounds (16/26, 11/15 and 9/12 mice tested for GP276, GP33 
and NP396, respectively; Fig. 3B). When broken down in early and late phases of chronic 
infection (day 9-20 vs. day 20-100), the average epitope-specific CTL selection pressure (κ) 
on GP276 and GP33 did not differ significantly between the two time windows, yet for 
NP396 was higher in the late phase of infection (Fig. 3C). Furthermore, the average CTL 
selection pressure in the late phase of infection (day 20-100) was significantly above 
BALB/c backgrounds for all three epitopes tested. These results documented that antiviral 
CTL selection pressure was not lost during the chronic phase of infection, which is in line 
with earlier reports on at least partially retained CTL killing capacity during chronic Cl13 
infection (20, 27). Next we analyzed the timing of CTL selection pressure at the level of 
individual C57BL/6 mice. We confirmed the trend for early onset CTL pressure on the 
GP276 and GP33 epitopes, whereas NP396-specific CTL selection tended to occur later 
(Fig. 3D). A bootstrap analysis was performed to investigate overarching patterns in TDSP, 
which characterize its timing across all mice despite considerable inter-individual 
variability. The TDSP 95% confidence interval (gray in Fig. 3E) confirmed that C57BL/6 
mice on average exerted GP276-specific CTL pressure during the first period of persistent 
infection up until day 50. The average GP33-specific selection pressure was biphasic, with 
early and late peaks. This pattern may be reflective of two distinct GP33-specific CTL 
populations restricted by H2-Kb- and H2-Db, respectively, yet prevented a meaningful 
statistical assessment of CTL timing. In concordance with the results of Fig. 3C, NP396-
specific CTL efficacy was significant at the cohort level in a later phase between around day 
30-80 of infection (Fig. 3E). Measurements of GP276-specific CTL frequencies in 
peripheral blood have failed to reveal a correlation with normalized epitope-specific CTL 
pressure (κ, Fig. 4). This finding was compatible with earlier observations that the 
quantitative assessment of virus-specific CTLs in peripheral blood of HIV patients showed 
little correlation to viral loads (36 , 37).
Discussion
The present quantification and characterization of antiviral CTL efficacy adds to our 
understanding how the immune system can prevail in chronic infection. Immunotherapeutic 
interventions bear considerable potential for treating persistent viral diseases, notably in 
HBV (38), and should aim for mimicking successful immune responses in spontaneous 
controllers.
The mechanisms underlying differential epitope-specific timing of selection pressure remain 
to be investigated. Several contributing factors can be envisioned including i) viral protein 
abundance (39) and resulting peptide ligand availability on target cells, ii) peptide – MHC 
binding affinity (23) and iii) the relative susceptibility of responding CTL populations to 
clonal deletion (12, 13). A better understanding thereof should help in the choice of target 
antigens and epitopes for antiviral immunotherapy.
Inter-individual variability of CTL selection pressure in genetically identical animals, both 
in terms of strength and timing, matches earlier reports from TCR spectratype analyses in 
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Cl13-infected mice (40). Differences in T cell repertoire due to stochastic events in TCR 
rearrangement and subsequent thymic selection may account for this, and were reported to 
influence HIV control (41). Similarly, de novo recruitment of thymic emigrants into the 
ongoing CTL response may contribute to time-dependent fluctuations in CTL selection 
pressure of individual mice (42).
Our observations suggest that therapeutic induction of antiviral CTL responses in chronic 
infection, even if partially dysfunctional by commonly used ex vivo criteria, can represent a 
correlate of immune control and a valuable goal of such interventions. This interpretation is 
in line with earlier reports that viremic Cl13-infected mice reject GP33- or NP396-pulsed 
syngeneic splenocytes in so-called «in vivo CTL assays». Similarly, NP396-specific CTLs 
were found to resurge in the late phase of infection (20 , 27), matching the timing of 
selection pressure on this epitope found here. When adoptively transferred and rested in an 
antigen-free environement, phenotypically « exhausted » CTLs can afford protection against 
subsequent virus challenge (28). Our report adds to these earlier observations by establishing 
and characterizing the protective antiviral efficacy of CTL populations in the chronically 
infected host.
Exhaustion is a gradual process (1, 13) and invidual cells of exhausted CTL populations 
cover a wide range of differential functionality (compare Fig. 1A,B and Fig. S1A-C). Hence, 
it seems plausible that subsets of more functional cells contributed overproportionally to the 
epitope-specific CTL pressure. It also is possible that fluctuations in CTL functionality 
account for the observed « waves » of TDSP.
The novel approach outlined herein provides a means to directly determine the impact of 
defined CTL specificities on viral loads, thus lending itself to future studies aimed at 
validating immune correlates of CTL efficacy. Specific CTL numbers are likely of relevance 
but their abundance in peripheral blood seems insufficient a predictor for antiviral efficacy 
(Fig. 4, (36, 37, 43)). Potential qualitative correlates of CTL efficacy comprise, among 
others, functional avidity (44), proliferative capacity (45), polyfunctionality (46), lytic 
granule loading (47), perforin expression (48), resistance to immunoregulation (49-51) and 
TCR clonotype composition (41). Unfortunately, peripheral blood may not represent the 
most relevant compartment to monitor in this context, albeit clearly the only option in 
longitudinal studies. This possibility is suggested by a dramatic skewing of virus-specific 
CTLs to LCMV-infected tissues such as bone marrow, liver, lungs and brain, in combination 
with compartment-related differences in CTL functionality (13). A timely assessment of 
such tissue compartments would require the experimental animal to be euthanized. This 
conflicts with the assessment of CTL efficacy, relying on the longitudinal sampling of serum 
from the same animals until CTL-mediated control is evident in reduced viral loads. 
Conversely, an analysis of CTL populations at such a later stage of the experiment would be 
confounded by differential antigen levels, since high viral antigen burden per se is known to 
compromise the functionality of antiviral CTLs (52). One potential strategy to overcome 
these limitations may consist in the identification of gene expression profiles or clonotype 
composition as biomarkers of CTL efficacy, an endeavor for which the technological 
approach presented herein seems well suited.
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Taken together, this longitudinal assessment of epitope-specific CTL selection pressure adds 
to our understanding how the immune system can prevail in chronic viral infection. Our 
findings are encouraging and should help in the rational design of CTL-based 
immunotherapies for persistent viral diseases.
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Figure 1. Characterization of exhausted CTLs and experimental approach for assessing their 
antiviral efficacy in protracted infection
A-B: We infected C57BL/6 mice with LCMV Armstrong (acute) or LCMV strain Clone 13 
(chronic). On day 20 we assessed GP33-specific CTLs by intracellular cytokine assay (A) 
and surface PD-1 expression (B). Bars in (A) represent the mean±SEM of three mice per 
group. Frequent cytokine-/marker-combinations are displayed (complete data sets in Fig. 
S1A-C). MFI in (B) is displayed as mean±SD of three mice. C: Experimental approach: 
Mice were co-infected with CTL epitope-mutant (MUT) and wildtype (WT) virus at the 
indicated dose. D: Amino acid sequences of the wildtype and mutant CTL epitopes. E: 
target sequences of the TaqMan RT-PCR assays utilized to individually quantify epitope-
mutant virus (normal viral nt sequence) and wildtype virus (tagged viral nt sequence) 
resulting in the same translation product. F : We infected C57BL/ mice with 2×105 PFU of 
either « tagged » wt Cl13 or « normal » wt Cl13 and monitored viremia over time. G-I: 
Schematic of viral load curves (F) with epitope-mutant:wildtype virus ratios (G) and time 
dependent selection co-efficients k(t) of prototypic selecting (C57BL/6, H-2b) or non-
selecting (BALB/c, H-2d) hosts. The shaded grey area in (I) denotes the 95% confidence 
interval of background k(t) determined in BALB/c mice.
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Figure 2. Epitope-specific CTL selection pressure in protracted LCMV infection
We infected C57BL/6 (top and center) and BALB/c mice (bottom) with 2×05 PFU of either 
ΔGP276, ΔGP33 or ΔNP396 virus, in combination with 2×106 PFU of wildtype LCMV (see 
schematic in Fig. 1C). Each virus was individually quantified in serum by TaqMan RT-PCR. 
Time-dependent selection coefficients k(t) (red lines) were calculated (see Materials & 
Methods and schematic in Fig. 1G-I). The grey shaded area denotes the 95% confidence 
interval of background k(t) in the absence of epitope-specific selection pressure. 
Representative C57BL/6 mice with either strong (top) or weak/absent selection pressure 
(center) are shown in comparison to non-selecing BALB/c mice (bottom). Analogous plots 
for all mice tested are displayed in Figs. S2-S4.
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Figure 3. Interindividual diversity, magnitude and timing of epitope-specific CTL selection 
pressure
A: Superimposition of k(t) curves from individual C57BL/6 (left) and BALB/c (right) mice, 
assessing selection pressure on the respective epitopes. B: Symbols represent the average 
selection pressure, κ, for individual C57BL/6 (white circles) and BALB/c mice (black 
circles) on the indicated epitopes over 100 days. Horizontal dashed lines denote the 
respective highest values recorded in BALB/c mice. C: Symbols represent the average 
epitope-specific selection pressure, κ, for individual C57BL/6 (white symbols) and BALB/c 
mice (black synbols) calculated for the period from day 9-20 or from day 20-100, as 
indicated. For pair-wise comparisons paired t tests (C57BL/6 d9-20 vs. C57BL/6 d20-100) 
and unpaired t tests (C57BL/6 d20-d100 vs. BALB/c d20-d100) were used. The resulting p-
values were subject to Bonferroni correction for multiple comparisons. D: Time windows 
during which the TDSP k(t) curves of individual mice (Fig. 2 and Figs. S2-S4) are above the 
95% confidence interval of background noise (see Methods). Individual mice are displayed 
as vertical lines, with thick segments denoting detectable selection pressure. Only C57BL/6 
mice with average selection coefficients above BALB/c backgrounds (dashed lines in Fig. 
3B) were included in the analysis. E: Derived TDSP based on all mice shown in (D). The 
mean (red line) and 95% confidence interval (grey shaded) of 10,000 bootstrap replicates are 
shown. The dashed line indicates the zero reference line, above which selection is recorded.
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Figure 4. Lack of correlation between normalized GP276-specific selection pressure and GP276-
specific CD8+ T cell frequencies in peripheral blood
We infected C57BL/6 with 2×105 PFU of ΔGP276 virus in combination with 2×106 PFU of 
wildtype LCMV as outlined in Fig. 2 and Fig. S2. In one out of 3 analogous experiments 
summarized in this manuscript, we determined GP276-specific CD8+ T cell frequencies in 
peripheral blood on day 40 after infection by using MHC class I tetramers. Symbols 
represent individual mice. Normalized GP276-specific selection pressure as displayed in 
Fig. 3B is plotted against the percentage Tet+ cells amongst CD8+B220- lymphocytes. 
Pearson correlation coefficient and p-value are indicated.
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